



11W1642

PTO/SB/21 (08-03)

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	09/671,953
		Filing Date	September 27, 2000
		First Named Inventor	Meares, Claude F.
		Art Unit	1642
		Examiner Name	Helms, Larry R.
Total Number of Pages in This Submission	8	Attorney Docket Number	61818-5014-US

### ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <ul style="list-style-type: none"> <li>• Return postcard</li> <li>• </li> </ul>	
			<input type="checkbox"/> Drawing(s)
			<input type="checkbox"/> Licensing-related Papers
			<input type="checkbox"/> Petition
			<input type="checkbox"/> Petition to Convert to a Provisional Application
			<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address
			<input type="checkbox"/> Terminal Disclaimer
			<input type="checkbox"/> Request for Refund
			<input type="checkbox"/> CD, Number of CD(s)
			<input type="checkbox"/> After Allowance Communication to Group
			<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
			<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)

Remarks

The Commissioner is authorized to charge any additional fees to Deposit Account 50-0310.

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual	Morgan, Lewis & Bockius LLP Nan Wu	Reg. No. 43,360
Signature		
Date	September 13, 2005	

### CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Judi Stillwell		
Signature		Date	September 13, 2005



**PATENT**  
Attorney Docket No.: 061818-5014-US  
Client Ref. No. 2000-123-3

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Confirmation No. 8313

MEARES et al.

Examiner: Helms, Larry R.

Application No.: 09/671,953

Technology Center/Art Unit: 1642

Filed: September 27, 2000

**AMENDMENT**

For: ENGINEERING ANTIBODIES  
THAT BIND IRREVERSIBLY

Customer No.: 43850

Commissioner for Patent  
P.O. Box 1450  
Alexandria VA 22313-1450

Sir:

Applicants respectfully request consideration of the above-referenced patent application in view of the amendments and remarks presented herein.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.

**Remarks** begin on page 6 of this paper.

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings of claims in the application. Claim 25 is amended.

**LISTING OF CLAIMS:**

1. (Previously Presented) A mutant antibody comprising a reactive site not present in the wild-type of said antibody and six complementarity determining regions (CDRs)